Cover Image
市場調查報告書

頭頸椎癌症:治療藥市場分析

Head and Neck Cancer: Full Disease Coverage

出版商 Datamonitor Healthcare 商品編碼 603962
出版日期 內容資訊 英文 221 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
頭頸椎癌症:治療藥市場分析 Head and Neck Cancer: Full Disease Coverage
出版日期: 2017年12月15日 內容資訊: 英文 221 Pages
簡介

本報告提供頭頸椎癌症治療藥市場相關調查分析,提供市場預測,治療,流行病學,上市藥,開發平台藥物趨勢等系統性資訊。

預測:頭頸椎癌症

  • 摘要整理
  • 市場概要·趨勢
  • 市場定義·手法
  • durvalumab
  • Erbitux (cetuximab)
  • Gilotrif (afatinib)
  • Javlor (vinflunine ditartrate)
  • Keytruda (pembrolizumab)
  • Multikine
  • Opdivo (nivolumab)
  • Reolysin
  • TS-1 (gimeracil/oteracil potassium/tegafur)
  • 一次調查手法

治療:頭頸椎癌症

  • 摘要整理
  • 一次調查手法
  • 疾病定義·診斷
  • 患者區分
  • 目前治療選擇
  • 處方趨勢

流行病學:頭頸椎癌症

  • 摘要整理
  • 疾病的背景
  • 手法
  • 預測
  • 流行病學者的考察
  • 優勢·規定
  • 參考文獻
  • 附錄

上市藥:頭頸椎癌症

  • 摘要整理
  • 產品概要
  • 產品簡介:Erbitux

開發平台:頭頸椎癌症

  • 摘要整理
  • 臨床開發平台概要
  • 最近開發中止的藥物
  • 比較療法
  • 產品簡介 (後期) :Gilotrif
  • 產品簡介 (後期) :Javlor
  • 產品簡介 (後期) :Keytruda
  • 產品簡介 (後期) :Multikine
  • 產品簡介 (後期) :Opdivo
  • 產品簡介 (後期) :Reolysin
  • 產品簡介 (後期) :durvalumab
目錄

DISEASE OVERVIEW

Head and neck cancer is the sixth most common cancer worldwide, and includes malignancies that can originate in the oral cavity, salivary glands, sinuses, and throat. Around 90% of cases have an epithelial origin, which present as squamous cell carcinomas. Environmental factors such as tobacco smoking and alcohol consumption greatly increase the risk of developing head and neck cancers. If diagnosed at an early stage, treatment for these cancers can be curative; however, the majority of patients are diagnosed when the disease is advanced, resulting in the need for more than one treatment modality.

MARKET SNAPSHOT

The head and neck cancer market is projected to reach $2.8bn in value by 2026, with growth driven by immunotherapies.

Erbitux continues to be the primary targeted therapy prescribed for the treatment of advanced head and neck cancer.

The incident population of this common cancer is predicted to increase over the forecast period of 2016-36.

Erbitux's position as the leading targeted therapy for SCCHN is being challenged as immunotherapies enter the market.

Immunotherapy developers will look to minimize direct competition in SCCHN by targeting new patient settings.

TABLE OF CONTENTS

FORECAST: HEAD AND NECK CANCER

  • Executive Summary
  • Market Overview and Trends
  • Market Definition and Methodology
  • durvalumab
  • Erbitux (cetuximab)
  • Gilotrif (afatinib)
  • Javlor (vinflunine ditartrate)
  • Keytruda (pembrolizumab)
  • Multikine
  • Opdivo (nivolumab)
  • Reolysin
  • TS-1 (gimeracil/oteracil potassium/tegafur)
  • Primary Research Methodology

TREATMENT: HEAD AND NECK CANCER

  • Executive Summary
  • Primary Research Methodology
  • Disease Definition and Diagnosis
  • Patient Segmentation
  • Current Treatment Options
  • Prescribing Trends

EPIDEMIOLOGY: HEAD AND NECK CANCER

  • Executive Summary
  • Disease Background
  • Methodology
  • Forecast
  • Epidemiologist Insight
  • Strengths and Limitations
  • Bibliography
  • Appendix: Additional Sources

MARKETED DRUGS: HEAD AND NECK CANCER

  • Executive Summary
  • Product Overview
  • Product profile: Erbitux

PIPELINE: HEAD AND NECK CANCER

  • Executive Summary
  • Clinical Pipeline Overview
  • Recently Discontinued Drugs
  • Comparator Therapy
  • Product profile (late stage): Gilotrif
  • Product profile (late stage): Javlor
  • Product profile (late stage): Keytruda
  • Product profile (late stage): Multikine
  • Product profile (late stage): Opdivo
  • Product profile (late stage): Reolysin
  • Product profile (late stage): durvalumab

LIST OF FIGURES

  • Figure 1: SCCHN drug sales in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Figure 2: SCCHN drug sales in the US, Japan, and five major EU markets, by status ($m), 2015-24
  • Figure 3: SCCHN drug sales in the US, by status ($m), 2015-24
  • Figure 4: SCCHN drug sales in Japan, by status ($m), 2015-24
  • Figure 5: SCCHN drug sales in the five major EU markets, by status ($m), 2015-24
  • Figure 6: Methodology flow
  • Figure 7: Price sources and calculations, by country
  • Figure 8: Durvalumab sales forecast for SCCHN in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Figure 9: Erbitux sales forecast for SCCHN in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Figure 10: Gilotrif sales forecast for SCCHN in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Figure 11: Javlor sales forecast for SCCHN in the five major EU markets, by country ($m), 2015-24
  • Figure 12: Keytruda sales forecast for SCCHN in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Figure 13: Multikine sales forecast for SCCHN in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Figure 14: Opdivo sales forecast for SCCHN in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Figure 15: Reolysin sales forecast for SCCHN in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Figure 16: TS-1 sales forecast for SCCHN in Japan ($m), 2015-24
  • Figure 17: HPV screening rates and outcomes among SCCHN patients, by country
  • Figure 18: Proportion of prevalent SCCHN patients in each stage of disease, by country
  • Figure 19: Proportion of Stage I and Stage II SCCHN patients receiving each treatment type, by country
  • Figure 20: Percentage of Stage III SCCHN patients receiving each treatment type, by country
  • Figure 21: Percentage of Stage III SCCHN patients receiving neoadjuvant therapy, adjuvant therapy, or both, by country
  • Figure 22: Top three regimens used in the adjuvant treatment of Stage III SCCHN patients, by country
  • Figure 23: Percentage of Stage IV SCCHN patients receiving each treatment type, by country
  • Figure 24: Top three regimens used in the first-line treatment of Stage IV SCCHN patients who receive pharmacological therapy without surgery, by country
  • Figure 25: Percentage of Stage IV SCCHN patients who progress from first- to second-line therapy or from second- to thirdline therapy, by country
  • Figure 26: Top three regimens used for the second-line treatment of Stage IV SCCHN patients, by country
  • Figure 27: Percentage of local relapse SCCHN patients receiving each treatment type, by country
  • Figure 28: Top three regimens used in the first-line treatment of local relapse SCCHN patients receiving pharmacological therapy without surgery, by country
  • Figure 29: Top three regimens used in the second-line treatment of local relapse SCCHN patients, by country
  • Figure 30: Percentage of distant relapse SCCHN patients receiving each treatment type, by country
  • Figure 31: Top three regimens used in the first-line treatment of distant relapse SCCHN patients who receive pharmacological therapy without surgery, by country
  • Figure 32: Top three regimens used in the second-line treatment of distant relapse SCCHN patients, by country
  • Figure 33: Trends in incident cases of HNC in the US, Japan, and five major EU markets, 2016-36
  • Figure 34: Absolute change in incident cases of HNC in the US, Japan, and five major EU markets, 2016-36
  • Figure 35: Age-specific trends in incident cases of HNC in the US, Japan, and five major EU markets, by country, 2016-36
  • Figure 36: Erbitux for head and neck cancer - SWOT analysis
  • Figure 37: Datamonitor Healthcare's drug assessment summary of Erbitux for head and neck cancer
  • Figure 38: Datamonitor Healthcare's drug assessment summary of Erbitux for head and neck cancer
  • Figure 39: Gilotrif for head and neck cancer - SWOT analysis
  • Figure 40: Datamonitor Healthcare's drug assessment summary of Gilotrif for head and neck cancer
  • Figure 41: Datamonitor Healthcare's drug assessment summary of Gilotrif for head and neck cancer
  • Figure 42: Javlor for head and neck cancer - SWOT analysis
  • Figure 43: Datamonitor Healthcare's drug assessment summary of Javlor for head and neck cancer
  • Figure 44: Datamonitor Healthcare's drug assessment summary of Javlor for head and neck cancer
  • Figure 45: Keytruda for head and neck cancer - SWOT analysis
  • Figure 46: Datamonitor Healthcare's drug assessment summary of Keytruda for head and neck cancer
  • Figure 47: Datamonitor Healthcare's drug assessment summary of Keytruda for head and neck cancer
  • Figure 48: Multikine for head and neck cancer - SWOT analysis
  • Figure 49: Datamonitor Healthcare's drug assessment summary of Multikine for head and neck cancer
  • Figure 50: Datamonitor Healthcare's drug assessment summary of Multikine for head and neck cancer
  • Figure 51: Opdivo for head and neck cancer - SWOT analysis
  • Figure 52: Datamonitor Healthcare's drug assessment summary of Opdivo for head and neck cancer
  • Figure 53: Datamonitor Healthcare's drug assessment summary of Opdivo for head and neck cancer
  • Figure 54: Reolysin for head and neck cancer - SWOT analysis
  • Figure 55: Datamonitor Healthcare's drug assessment summary of Reolysin for head and neck cancer
  • Figure 56: Datamonitor Healthcare's drug assessment summary of Reolysin for head and neck cancer
  • Figure 57: Durvalumab for head and neck cancer - SWOT analysis
  • Figure 58: Datamonitor Healthcare's drug assessment summary of durvalumab for head and neck cancer
  • Figure 59: Datamonitor Healthcare's drug assessment summary of durvalumab for head and neck cancer

LIST OF TABLES

  • Table 1: SCCHN drug sales in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 2: SCCHN drug sales in the US, Japan, and five major EU markets, by brand and status ($m), 2015-24
  • Table 3: SCCHN drug sales in the US, by brand and status ($m), 2015-24
  • Table 4: SCCHN drug sales in Japan, by brand and status ($m), 2015-24
  • Table 5: SCCHN drug sales in the five major EU markets, by brand and status ($m), 2015-24
  • Table 6: Summary of drug classes, molecules, and brands included in the SCCHN patient-based forecast
  • Table 7: Exchange rates used for calculating prices
  • Table 8: Patent expiry dates for key marketed brands in SCCHN, by region
  • Table 9: Estimated approval dates of key late-stage pipeline products in SCCHN, by region
  • Table 10: Durvalumab sales forecast for SCCHN in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 11: Durvalumab patient numbers for SCCHN in the US, Japan, and five major EU markets, by country, 2015-24
  • Table 12: Erbitux sales forecast for SCCHN in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 13: Erbitux patient numbers for SCCHN in the US, Japan, and five major EU markets, by country, 2015-24
  • Table 14: Gilotrif sales forecast for SCCHN in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 15: Gilotrif patient numbers for SCCHN in the US, Japan, and five major EU markets, by country, 2015-24
  • Table 16: Javlor sales forecast for SCCHN in the five major EU markets, by country ($m), 2015-24
  • Table 17: Javlor patient numbers for SCCHN in the five major EU markets, by country, 2015-24
  • Table 18: Keytruda sales forecast for SCCHN in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 19: Keytruda patient numbers for SCCHN in the US, Japan, and five major EU markets, by country, 2015-24
  • Table 20: Multikine sales forecast for SCCHN in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 21: Multikine patient numbers for SCCHN in the US, Japan, and five major EU markets, by country, 2015-24
  • Table 22: Opdivo sales forecast for SCCHN in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 23: Opdivo patient numbers for SCCHN in the US, Japan, and five major EU markets, by country, 2015-24
  • Table 24: Reolysin sales forecast for SCCHN in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 25: Reolysin patient numbers for SCCHN in the US, Japan, and five major EU markets, by country, 2015-24
  • Table 26: TS-1 sales forecast for SCCHN in Japan ($m), 2015-24
  • Table 27: TS-1 patient numbers for SCCHN in Japan, 2015-24
  • Table 28: Physicians surveyed for the squamous cell carcinoma of the head and neck primary research study, 2015
  • Table 29: Physicians surveyed for the head and neck cancer primary research study, 2017
  • Table 30: Oral cavity and pharynx cancer five-year survival rates, by stage at diagnosis, 2007-13
  • Table 31: TNM stage classification
  • Table 32: Leading treatments for SCCHN
  • Table 33: Head and neck cancer site codes according to ICD-10
  • Table 34: Cancer registry databases used as a source of HNC incidence data, by country
  • Table 35: Forecasting methodology for HNC incidence, by country, age group, and gender
  • Table 36: Sources of survival data used to estimate HNC prevalence, by country/region
  • Table 37: Diagnosed incident cases of HNC in the US, Japan, and five major EU markets, by country, 2016-36
  • Table 38: Age-specific incident cases of HNC in the US, Japan, and five major EU markets, by country, 2016
  • Table 39: Gender-specific incident cases of HNC in the US, Japan, and five major EU markets, by country, 2016
  • Table 40: Validation of forecast estimates against benchmark estimates
  • Table 41: Key marketed drugs for head and neck cancer
  • Table 42: Erbitux drug profile
  • Table 43: Erbitux pivotal trial data in head and neck cancer
  • Table 44: Late-stage pipeline products in development for head and neck cancer
  • Table 45: Late-stage compounds that were recently discontinued for head and neck cancer
  • Table 46: Erbitux drug profile
  • Table 47: Gilotrif drug profile
  • Table 48: Gilotrif Phase III trials in head and neck cancer
  • Table 49: Gilotrif Phase III data in head and neck cancer
  • Table 50: Javlor drug profile
  • Table 51: Javlor Phase III trials in head and neck cancer
  • Table 52: Keytruda drug profile
  • Table 53: Keytruda Phase III trials in head and neck cancer
  • Table 54: Keytruda topline early-phase data in head and neck cancer
  • Table 55: Overview of Phase Ib trial data for Keytruda in PD-L1-positive head and neck cancer patients
  • Table 56: Multikine drug profile
  • Table 57: Multikine Phase III trials in head and neck cancer
  • Table 58: Overview of Phase II trial data for Multikine in head and neck cancer
  • Table 59: Opdivo drug profile
  • Table 60: Ongoing Opdivo Phase III trials in head and neck cancer
  • Table 61: Opdivo Phase III data in head and neck cancer
  • Table 62: Reolysin drug profile
  • Table 63: Reolysin Phase III data in head and neck cancer
  • Table 64: Durvalumab drug profile
  • Table 65: Durvalumab Phase III and pivotal Phase II trials in head and neck cancer
Back to Top